World’s First Integrated Imaging Service for Long-COVID approved by UK’s MHRA.
The UK’s Medicines & Healthcare products Regulatory Agency (MHRA) approved the use of COVERSCAN MD, an MRI-based technology that maps the effects of COVID-19 on several of the body’s key organs, developed by Perspectum.
With 1 in 20 COVID-19 patients predicted to experience ongoing symptoms, or “Long-COVID”, COVERSCAN MD quickly and safely provides medical professionals with the information critically needed to assess and evaluate patients.
Perspectum’s COVERSCAN MD technology enables healthcare providers to identify coronavirus-related systemic organ damage through scans of patients’ hearts, lungs, livers, as well as other internal organs, and to assess the impact of SARS-CoV-2 infections.
With the use of COVERSCAN MD, UK doctors will now have a technology to add to the arsenal of tools used to assess and evaluate patients with Long-COVID, while at the same time gain a greater understanding of its symptoms and long-term impact on different organ systems.
Farewell from Claire Bloomfield
September 9, 2021
Final words from our departing CEO, Claire Bloomfield As I leave NCIMI today, I am reflecting on all the hard…
NCIMI events, speaking engagements, conferences and webinars
September 1, 2021
Optellum collaborating with Johnson & Johnson
August 18, 2021
Ecosystem approach will bring AI benefits to the clinical front line
August 12, 2021